Condition: Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia · Sponsor: Goethe University
The current Standard of Care (SoC) in younger patients with Ph+ ALL is Imatinib in combination with low-dose chemotherapy, change of TKI in case of persistent MRD above 10-3 after consolidation I and indication for stem cell transplantation. The EVOLVE trial aims to answer three questions challenging the current SoC: Use of Ponatinib compared to Imatinib both in combination with low-dose chemotherapy and consolidation I (randomization I). In MRD good responders: Omit end of therapy in primary care and indication for SCT but continue therapy with TKI, chemotherapy and Blinatumomab as additional antileukemic compound (randomization II). In MRD poor responders: Omit indication for TKI change but give instead Blinatumomab followed by end of therapy in primary care and indication for SCT (non-randomized).
This description comes directly from the study's public registry record.
Nicola Goekbuget, MD · 0049-6963016365 · goekbuget@em.uni-frankfurt.de
Fabian Lang, MD · 0049-69630183044 · f.lang@med.uni-frankfurt.de
Always discuss trial participation with your own doctor first.
| Uniklinik RWTH Aachen | Aachen, Germany | Recruiting |
| Klinikum Aschaffenburg | Aschaffenburg, Germany | Recruiting |
| Klinikum Augsburg | Augsburg, Germany | Recruiting |
| Helios Klinikum Bad Saarow | Bad Saarow, Germany | Recruiting |
| Klinikum Bayreuth | Bayreuth, Germany | Recruiting |
| Vivantes Klinikum am Urban | Berlin, Germany | Recruiting |
| Charité Universitätsmedizin Berlin | Berlin, Germany | Recruiting |
| Vivantes Klinikum Neukölln | Berlin, Germany | Recruiting |
| Helios Klinikum Berlin-Buch | Berlin, Germany | Recruiting |
| Charite Berlin Virchow Klinikum | Berlin, Germany | Recruiting |
| Evangelisches Krankenhaus Bielefeld | Bielefeld, Germany | Recruiting |
| UK Knappschaftskrankenhaus Bochum | Bochum, Germany | Recruiting |
+ 73 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06061094